|
|
 |
 |
104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft 2006
Abstract
Abstract
SA.01.11 Comparison of 2.5 and 5mg/kg systemic Bevacizumab (Avastin®) in patients with neovascular age-related macular degeneration Michels S.1, Prager F.1, Geitzenauer W.1, Vormittag L.2, Kornek G.2, Rosenfeld P.3, Schmidt-Erfurth U.1
1Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien; 2Klinik für Onkologie, Medizinische Universität Wien; 3Bascom Palmer Eye Institute, University of Miami Objective: To compare 2.5 and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration (AMD).
Methods: In a prospective cohort study, approved by the local ethics committee, 14 eyes (8 patients) were treated with 5 mg/kg and 16 eyes (9 patients) with 2.5 mg/kg intravenous bevacizumab. All patients received 3 initial i.v. infusions at 2 week intervals and were monitored at least every 4 weeks by ETDRS visual acuity, optical coherence tomography (OCT), and fluorescein angiography (FA).
Results: Both groups showed a comparable initial treatment response at month 3. Mean visual acuity (VA) increased in the 5 mg/kg group from 53.6 letters (~20/80-2) at baseline to 65.7 letters (~20/50) at month 3 (p=0.0002) and remained stable with 65.9 letters (20/50) at months 6 (p=0.001). Respectively, the 2.5mg/kg group showed an increase in VA from 57 (20/80+2) to 63.5 (20/50-2) (p=0.0013) and 68.7 letters (20/40-2) (p=0.04). Baseline mean central retinal thickness, as measured by OCT, was 366µm in the 5mg/kg and 333µm in the 2.5 mg/kg group. Within 3 months CRT decreased in both groups to 245µm (p=0.002) and 218µm (p=0.035) respectively, and remained stable at month 6 (256µm (p=0.02) /220µm (p=0.039)). However, the need for retreatment within 6 months was higher in the 2.5mg group. Except for an initial, moderate increase in blood pressure, no further systemic adverse events were found.
Conclusions: Systemic bevacizumab therapy using 2.5 and 5mg/kg showed promising and comparable treatment results up to 6 months follow-up. This treatment modality might be of advantage especially in patients with bilateral neovascular AMD.
Zurück | Back
|
